Evidence map›Paper›PMID 33386810›Full record

ArticleJournal of neuromuscular diseases2021

Elucidation of the Genetic Cause in Dutch Limb Girdle Muscular Dystrophy Families: A 27-Year's Journey.

L Ten Dam, M de Visser, Ieke B Ginjaar, Hermine A van Duyvenvoorde, Silvana van Koningsbruggen, Anneke J van der Kooi

Open access · greenAbstract read
In one paragraph

Article in Journal of neuromuscular diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. TheActa myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2024
    Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

L Ten DamDepartment of Neurology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
M de VisserDepartment of Neurology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Ieke B GinjaarDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
Hermine A van DuyvenvoordeDepartment of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
Silvana van KoningsbruggenDepartment of Clinical Genetics, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
Anneke J van der KooiDepartment of Neurology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Amsterdam Neuroscience · NLLeiden University · NLUniversity of Amsterdam · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA Dutch cohort of 105 carefully selected limb girdle muscular dystrophy (LGMD) patients from 68 families has been subject to genetic testing over the last 20 years. After subsequent targeted gene analysis around two thirds (45/68) of the families had received a genetic diagnosis in 2013.

objectiveTo describe the results of further genetic testing in the remaining undiagnosed limb girdle muscular dystrophy families in this cohort.

methodsIn the families of the cohort for whom no genetic diagnosis was established (n = 23) further testing using Sanger sequencing, next generation sequencing with gene panel analysis or whole-exome sequencing was performed. In one case DNA analysis for facioscapulohumeral dystrophy type 1 was carried out.

resultsIn eight families no additional genetic tests could be performed. In 12 of the remaining 15 families in which additional testing could be performed a genetic diagnosis was established: two LGMDR1 calpain3-related families with CAPN3 mutations, one LGMDR2 dysferlin-related family with DYSF mutations, three sarcoglycanopathy families (LGMDR3-5 α-, β- and γ-sarcoglycan-related) with SGCA/SGCB/SGCG mutations, one LGMDR8 TRIM 32-related family with TRIM32 mutations, two LGMDR19 GMPPB-related families with GMPPB mutations, one family with MICU1-related myopathy, one family with FLNC-related myopathy and one family with facioscapulohumeral dystrophy type 1. At this moment a genetic diagnosis has been made in 57 of the 60 families of which DNA was available (95%).

conclusionA genetic diagnosis is obtained in 95% of the families of the original Dutch LGMD cohort of which DNA was available.

Indexed as

AdolescentAdultCalcium-Binding ProteinsCalpainCation Transport ProteinsChildDysferlinExome SequencingFemaleGenetic TestingHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMitochondrial Membrane Transport ProteinsMuscle ProteinsCalcium-Binding ProteinsCalpainCAPN3 protein, humanCation Transport ProteinsDysferlinDYSF protein, humanMICU1 protein, humanMitochondrial Membrane Transport ProteinsMuscle ProteinsTranscription FactorsTRIM32 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligasesgene panelLimb girdle muscular dystrophysanger sequencingwhole exome sequencing

Identifiers

PMID33386810
PMCPMC9789482
OpenAlexW3114177615

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.